ArticleJournal of Cancer2017
The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC).
Article in Journal of Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Research on Targeted Therapy for Malignant Tumors of the Biliary Tract.OncoTargets and therapy · 2026Review
- Global gene expression landscape of gallbladder cancer and advances in targeted therapeutic strategies.World journal of clinical oncology · 2025Review
- Immunohistochemistry in intrahepatic cholangiocarcinoma: histological subtyping and drug selection.Frontiers in oncology · 2025Review
- HGF/c-MET axis contributes to CLL cell survival by regulating multiple mechanisms making it a potential therapeutic target for CLL treatment.Frontiers in pharmacology · 2025Article
- Liquid biopsy in gallbladder carcinoma: Current evidence and future prospective.The journal of liquid biopsy · 2024Review
- EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance.The oncologist · 2024Article
- c-MetBiomedicines · 2023Article
- In Silico Target Identification of Galangin, as an Herbal Flavonoid against Cholangiocarcinoma.Molecules (Basel, Switzerland) · 2022Article
- Overview of current targeted therapy in gallbladder cancer.Signal transduction and targeted therapy · 2020Review
- TargetingCancer discovery · 2020Review
- Prevalence and Clinicopathological Significance of MET Overexpression and Gene Amplification in Patients with Gallbladder Carcinoma.Cancer research and treatment · 2020Article
- Targets for therapy in biliary tract cancers: the new horizon of personalized medicine.Chinese clinical oncology · 2020Review
- Upregulation of miR‑132‑3p in cholangiocarcinoma tissues: A study based on RT‑qPCR, The Cancer Genome Atlas miRNA sequencing, Gene Expression Omnibus microarray data and bioinformatics analyses.Molecular medicine reports · 2019Article
- Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.Journal of gastrointestinal oncology · 2019Article
- Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.Cell death & disease · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.